{"nctId":"NCT01069172","briefTitle":"Study of the Femtosecond Laser System as Compared to Continuous Curvilinear Capsulorhexis for Cataract Surgery","startDateStruct":{"date":"2010-02"},"conditions":["Cataract"],"count":30,"armGroups":[{"label":"FS Laser Surgery","type":"EXPERIMENTAL","interventionNames":["Device: FS Laser Surgery"]},{"label":"CCC Surgery","type":"ACTIVE_COMPARATOR","interventionNames":["Procedure: CCC Surgery"]}],"interventions":[{"name":"FS Laser Surgery","otherNames":["OptiMedica Catalysâ„¢ Precision Laser System (Catalys System) = femtosecond laser; Alcon Infiniti System = U/S (ultrasound) phacoemulsification system"]},{"name":"CCC Surgery","otherNames":["Alcon Infiniti System = U/S (ultrasound) phacoemulsification system."]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Able and willing to comply with the treatment/follow-up schedule and requirements\n* Able to understand and provide written Informed Consent\n* ETDRS (Early Treatment of Diabetic Retinopathy Study) visual acuity equal to or worse than 20/32 (best corrected)\n* Age between 50 and 80 years old\n* Pupil dilates to at least 7 mm\n* Subject able to fixate\n* Grade 1-4 nuclear sclerotic cataract (Lens Opacities Classification System - LOCS III)\n* Axial length between 22 and 26 mm\n\nExclusion Criteria:\n\n* Pregnant, intending to become pregnant during course of the study, less than 3 months postpartum or less than 6 weeks after completion of breastfeeding\n* Participation in a study of another device or drug within 3 months prior to study enrollment or during this study, and as per the Investigator's careful discretion, as long as not contradictory to any of the above criteria\n* Any condition which, in the Investigator's opinion, would make it unsafe (for the subject or for the study personnel) to treat the subject as part of this research study or for which cataract surgery is contraindicated\n* Anterior chamber depth (anterior corneal surface to anterior capsule margin) less than 2.5 mm via IOL Master (Zeiss).\n* History of prior ocular surgery\n* History of ocular trauma\n* Co-existing ocular disease affecting vision\n* History or current use of alpha-1 antagonist medication (e.g., Flomax)\n* Known sensitivity to planned concomitant medications","healthyVolunteers":false,"sex":"ALL","minimumAge":"50 Years","maximumAge":"80 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Deviation From Intended Capsulotomy Diameter","description":"Capsulotomy diameter measured during surgery for both the experimental and control groups.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"26.8","spread":"24.6"},{"groupId":"OG001","value":"339.1","spread":"248.0"}]}]}]},{"type":"SECONDARY","title":"Cumulative Dissipated Energy (CDE)","description":"CDE (the amount of ultrasound energy delivered during phacoemulsification of the crystalline lens) used will be measured during surgery. CDE is a unit used for the Alcon Infinity System (the U/S phacoemulsification used in this study). It is not expressed in standard units such as watts or Joules. CDE, which accounts for the power and time of two ultrasound delivery modes (longitudinal and torsional), is calculated as follows:\n\nCDE = (Phaco time x average phaco power) + (torsional time x average torsional aptitude x 0.4)\n\n0.4 is a factor representing the approximate reduction of heat dissipated at the incision as compared to conventional phacoemulsification.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"11.58","spread":"8.35"},{"groupId":"OG001","value":"18.54","spread":"12.07"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":2,"n":29},"commonTop":["Elevated intraocular pressure"]}}}